Rating for BBIO
BridgeBio Pharma, Inc. (BBIO)
Last bridgebio pharma, inc. earnings: 3/2 08:29 am
Check Earnings Report
Company Research
Source: Benzinga
Impact Snapshot
Event Time:
BBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BBIO alerts
High impacting BridgeBio Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
BBIO
News
- BridgeBio Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on February 20, 2025 [Yahoo! Finance]Yahoo! Finance
- BridgeBio Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on February 20, 2025GlobeNewswire
- BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $49.00 price target on the stock.MarketBeat
- BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its price target raised by analysts at Scotiabank from $48.00 to $49.00. They now have a "sector outperform" rating on the stock.MarketBeat
- BEYONTTRA™ (acoramidis), the First Near Complete TTR Stabilizer (=90%), Approved by the European Commission to Treat ATTR-CM [Yahoo! Finance]Yahoo! Finance
BBIO
Earnings
- 11/12/24 - Beat
BBIO
Sec Filings
- 2/13/25 - Form SCHEDULE
- 1/31/25 - Form SCHEDULE
- 1/31/25 - Form 144
- BBIO's page on the SEC website